PharmTech Europe's June 2026 issue reflects the convergence of compliance burden, cost pressure, analytical complexity, and patient access.
PharmTech Europe June 2026
The CMA will improve Europe’s manufacturing resilience and lead to greater diversification and reduced reliance on single external suppliers.
European biotechnology companies are increasing patient access to innovative cell and gene therapies through decentralized next-generation manufacturing platforms.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma
2
The FDA Moves to Modernize Drug Manufacturing Registration
3
PharmTech Weekly Roundup–July 10, 2026
4
What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline
5